All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
During the EHA 2022 Congress, the MPN Hub was pleased to speak to Tiziano Barbui, Papa Giovanni XXIII Hospital, Bergamo, IT. We asked, Thrombotic events in MPN: What is the primary prophylaxis used to avoid the first arterial and venous events.
Thrombotic events in MPN: Primary prophylaxis to avoid the first arterial and venous events
Barbui begins by talking about managing thrombotic risk, and how primary prophylaxis can affect the thrombotic risk. Barbui also discusses drugs used to manage thrombosis, including aspirin, interferons, hydroxyurea, and ruxolitinib.
Polycythemia vera and essential thrombocythemia: 2021 updates
In a recent publication in the American Journal of Hematology, Tefferi and Barbui provided a review of the 2021 updates on the diagnosis, risk‐stratification, and management of...
Preventing thrombosis with ruxolitinib in polycythemia vera
Polycythemia vera (PV) is an MPN that is characterized by the overproduction of erythrocytes and may also be associated with an increase in leukocytes and thrombocytes. In most patients, PV...
Subscribe to get the best content related to MPN delivered to your inbox